

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12Q 1/32, C12N 9/04, G01N 21/64, 21/76	A1	(11) International Publication Number: WO 96/39534 (43) International Publication Date: 12 December 1996 (12.12.96)
(21) International Application Number: PCT/US96/09869 (22) International Filing Date: 6 June 1996 (06.06.96) (30) Priority Data: 08/467,712 6 June 1995 (06.06.95) US (71) Applicant: IGEN, INC. [US/US]; 16020 Industrial Drive, Gaithersburg, MD 20877 (US). (72) Inventor: MARTIN, Mark, T.; 516 Old Farm Court, N. Bethesda, MD 20852 (US). (74) Agents: RYAN, John, W. et al.; Igen, Inc., 16020 Industrial Drive, Gaithersburg, MD 20877 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: ELECTROCHEMILUMINESCENT ENZYME BIOSENSORS (57) Abstract Electrochemiluminescent enzymes, their preparation and use as biosensors are disclosed. Specifically, two appendages are covalently attached to a desired dehydrogenase enzyme; (1) a nicotinamide adenine cofactor or analog thereof, and (2) a luminescent ruthenium complex. For example, glucose concentration is the following way. A doubly-modified glucose dehydrogenase could oxidize glucose with concomitant reduction of the attached NAD ⁺ to NADH. Because NADH, but not NAD ⁺ , is able to interact with surface ruthenium to promote ECL, only enzyme molecules that have reacted with glucose will emit light from their ruthenium label in an ECL instrument. The relative close proximity of NADH and ruthenium on the enzyme surface enhances light emission as compared to the same concentrations in free solution. When NADH reduces ruthenium, it returns to become NAD ⁺ , permitting multiple cycles of ECL light emission from a single enzyme molecule. Such biosensors can be used in solution or bound to a solid surface. Assays employing the biosensor molecules can be performed on an IGEN Origen® Analyzer.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

5

ELECTROCHEMILUMINESCENT ENZYME BIOSENSORSBACKGROUND OF THE INVENTION1. Field of the Invention

The technical field is analytical biochemistry, especially as pertains to diagnostics. More specifically, the invention involves the preparation and use of novel enzyme-based biosensors which blend the useful properties of a tailored dehydrogenase with electrochemiluminescence (ECL) based assay format to detect and the quantify a specific analyte or analytes using conventional biosensor arrangements.

2. Background Information


Biosensors contain biomolecules, such as enzymes or antibodies, or whole-cell testers. Biosensors can be used for rapid, real-time detection of materials in environmental and/or clinical samples. The present biosensor invention involves the creation of enzyme-coenzyme-electrochemiluminescence tagged conjugates. Their development reflects a multidisciplinary effort. The background of the relevant technological areas will be discussed sequentially.

Assays based on electrochemiluminescence (ECL) are well known in the art and are finding expanding applications because of their accuracy, ease of use and freedom from radioactive materials.

A particularly useful ECL system is described in a paper by Yang et al, Bio/Technology, 12, pp. 193-194 (Feb. 1994). See also a paper by Massey, Biomedical Products, October 1992 as well as U.S. Patents 5,235,808 and 5,310,687, the contents of these papers and patents being incorporated herein by reference.

ECL processes have been demonstrated for many different molecules by several different mechanisms. In Blackburn et al (1991) Clin.Chem. 37/9, pp. 1534-1539,

the authors used the ECL reaction of ruthenium (II) tris(bipyridyl), $\text{Ru}(\text{bpy})_3^{2+}$, with tripropylamine (TPA) (Leland et al (1990) J. Electrochem. Soc. 137:3127-31) to demonstrate the technique. Salts of $\text{Ru}(\text{bpy})_3^{2+}$ are very
 5 stable, water-soluble compounds that can be chemically modified with reactive groups on one of the bipyridyl ligands to form activated species with which proteins, haptens, and nucleic acids are readily labeled. The activated form of the $\text{Ru}(\text{bpy})_3^{2+}$ used by Blackburn et al
 10 was $\text{Ru}(\text{bpy})_3^{2+}$ -NHS ester:



The creation of tailored enzyme conjugates is a developing area, especially in the clinical biochemical area. Ebeling et al. (U.S. Patent No. 5,250,415) utilized recombinant techniques to enhance the quality
 15 and stability of NAD/NADP and dependent glucose dehydrogenase (E.C. 1.1.1.42). Through the use of recombinant techniques, isoenzymes were produced in high quality and the enzymes display comparable stability over the range of temperatures between 20° and 50°C. The
 20 enzymes are disclosed as suitable for use as medical diagnostic applications.

The creation of semi-synthetic glucose oxidase involving the formation of enzyme conjugates having linked regenerative moieties has been attempted by
 25 certain research groups with some success. See Yomo et al., "Preparation and Kinetic Properties of 5-ethylphenazine-glucose-dehydrogenase-NAD⁺ conjugate, A Semi-Synthetic Glucose Oxidase," European J. Biochem.

(Germany), (September 15, 1991), Vol. 200(3), pp. 759-66. 5-ethylphenazine-glucose-dehydrogenase-NAD⁺ conjugate (EP(+)-Glc DH-NAD⁺) was prepared by linking both poly (ethylene glycol)-bound 5-ethyl-phenazine and poly
5 (ethylene glycol)-bound NAD⁺ to glucose dehydrogenase. This conjugate is a semi-synthetic enzyme having glucose oxidase activity using oxygen or 3-(4,5-dimethyl-2-thiazoyl)-2, 5-diphenyl-2lt-tetra zolium bromide (MTT) as an electron acceptor. The semi-synthetic oxidase has two
10 catalytic steps: reduction of the NAD⁺ moiety by the active site of the glucose dehydrogenase moiety and oxidation of the NADH moiety by another catalytic site of the ethylphenazine moiety.

The selective labelling of amino groups in
15 proteins such as beta-D-glucose: NAD(P⁺) 1-oxidoreductases (EC 1.1.1.47) has been demonstrated. Bozler et al. (Biochim. Biophys. Acta, Vol.749, No. 3, pp. 238-43) selectively labelled glucose dehydrogenase at a lysine group with (2-5¹-dimethyl amino naphthalene -1-sulfonamido) methylamidic acid methyl ester. The ester
20 was synthesized for the purpose of fluorescence labelling of amino groups of proteins. The incorporation of the dansyl group served as an extrinsic fluorescent probe which can be determined spectrophotometrically.

25 Biosensors are continually growing area of technology. The term biosensor encompasses a wide range of technologies and reflects multi-disciplinary efforts. There is a continuing need in this area for the enhancement of sensitivity, reliability and rapidity.

30 A common thread to biosensor technology is the use of a biological material in the measurement of analyte. This is a rather encompassing definition.

A representative text in this field, illustrating the blend of technologies, is Biosensor Design and Application, edited by Paul R. Mathewson and
35 John W. Finley, which was published in 1992 by American Chemical Society, Washington, D.C..

Biosensors, in addition to the requisite biological molecule, can include a variety of measuring systems, e.g. an electrode system comprising a measuring electrode and a luminescence counter wherein the reaction layer contacts the electrode system. The reaction layer typically comprises one molecule electron acceptor, a measuring enzyme and chemiluminescent sensor. The diversity of biosensor systems is evidenced by the devices such as those illustrated in U.S. Patent Nos. 5,324,835, 5,229,202 and 5,384,028.

Glucose biosensor giving stable measured results without NAD consumption are known. Such biosensors are useful for the qualitative or quantitative determination of one or more components in a liquid mixture by electrochemical regeneration of coenzyme. Typically, such an electrode comprises a redox polymer adsorbed on the surface of the electrode, one or more enzymes wherein at least one is a dehydrogenase and a coenzyme such as NADH, NADPH or their analogues. See Gordon et al, U.S. Patent No. 5,264,092.

Another approach is evidenced in U.S. Patent No. 5,340,722 (Wolfbeis et al.) which teaches a continuous and reversible determination using a biosensor which involves a flavin co-enzyme (FMN, FAD), oxidases and oxygenases. The assay is fluorescence based. During enzymatic oxidation the co-enzyme simultaneously transitions into a reduced form, which is then immediately reconverted into the oxidized form by means of oxygen. The transition from oxidized form to reduced form is linked to a change in fluorescence properties, which serve as the analytical parameter.

However, there still remains a need to further enhance the economy, reliability, sensitivity and responsiveness of biosensors.

SUMMARY OF THE INVENTION

Broadly stated, the invention contemplates an electrochemiluminescence based assay using a biosensor having a dehydrogenase which has been modified to properly position TAG and the desired nucleotide cofactor (coenzyme) near the active site. Such positioning enhances reaction times improves the energy efficiency of the system which improves accuracy, speed and reliability and the like for the detection of enzymes or their substrates and cofactors.

The object of the invention is to both enhance sensitivity and specificity of ECL-based assays and to conserve reagent usage.

The monitored or detected analyte is either the substrate of a dehydrogenase or a substance that can be converted into the substrate of a dehydrogenase. The dehydrogenase is the molecule that allows sensing of the analyte by an ECL instrument. It is also envisioned that the biosensor molecule of the invention can be used in conjunction with another enzyme or enzyme system which produces a product which is measured by the biosensor molecule. This would further increase the range of applications.

The dehydrogenase is not present in its natural form, but rather has been chemically-modified so that it has two unnatural appendages. One appendage is a covalently attached functional analog of NAD(P)^+ , NAD(P)H . Such enzymes have been made (Persson et al. 1991). This nicotinamide cofactor is specifically attached in a way that it can bind in the active site of the enzyme and function as a redox reagent as part of the natural enzyme mechanism. The second appendage is an ECL label such as a derivative of Ru(bpy)_3^{2+} . Such proteins have been made (Blackburn et al. 1991).

The way that the biosensor works is as follows:

(1) The analyte is oxidized by the NAD^+ form of the doubly-modified enzyme, causing the enzyme to be converted to the NADH form.

5 (2) In an ECL instrument, voltage will be applied to the enzyme, causing the NADH appendage to become oxidized by donating an electron to the luminescent ruthenium-containing appendage, which in turn emits light (Downey et al. 1992). As a result, NADH returns to become NAD^+ such that a second molecule of analyte can be oxidized and the cycle can be repeated. The demonstration of
10 electron transfer through ruthenium-labelled proteins has previously been accomplished (Pan et al. 1993; Wuttke et al.)

Some analytes (and their enzymes) that function in
15 the above mechanism are: glucose (glucose dehydrogenase), ethanol (alcohol dehydrogenase), and lactate (lactate dehydrogenase). It is envisioned, however, that other oxidoreductases such as those listed on pages 684-702 of the Enzymes (Academic Press (1979))
20 by M. Dixon and E. C. Webb could also be utilized. Their selection depends on the location of amino acids near the active site with sidechains which could be linked to either NAD or TAG moieties through an appropriate linking group, e.g. ester, thiol ether, etc..

25 The main advantages of this invention are:

(1) potential high sensitivity and low background. The fixed nature of the reagents (on a single molecule) is desirable because of entropic effects; their effective concentrations relative to each other will be very high
30 which will give substantially better yields (of light) than if they were free in solution.

(2) possibly lowered analysis cost over the same system in which the enzyme, NADH, and the ruthenium compound are free in solution. Because of this, lower
35 concentrations of the reagents will give results equivalent to results obtained with free reagents, and

also because one NADH molecule can be recycled, the cost of analysis will be reduced.

(3) combining three reagents into one molecule is more attractive for immobilized systems. It would be
5 extremely attractive to be able to immobilize biosensors so that they can be reused. If the enzyme alone were immobilized, the other reagents (NADH and $\text{Ru}(\text{bpy})_3^{2+}$) would need to be added for each analysis. In this
10 invention, all reagents could be immobilized in a way in which would be functional.

Devices employing biosensor molecules typically employ the molecule in an immobilized state. Immobilization provides stability to the molecule and ensures its continued presence in a desired area of the
15 device for optimal performance. Typical of the techniques used to immobilize the biosensor molecules of this invention are those disclosed on pages 3 through 34 of Methods of Enzymology, Vol. 136 (1987).

At the present time, a preferred use for the glucose
20 dehydrogenase of the invention is as a glucose biosensor. Functional glucose dehydrogenase has been made which has an immobilized NADH molecule (Persson et al., 1991). This modified enzyme could be reacted with $\text{Ru}(\text{bpy})_3^{2+}$ -NHS ester (IGEN, Inc., Rockville, MD) by conventional means
25 used to attach this compound to surface lysines present on antibodies (Blackburn et al., 1991). Such modification may result in one or more ruthenium appendages (multiple appendages are acceptable or even advantageous if the enzyme remains active). The doubly-
30 modified enzyme could be purified by dialysis or chromatography. Addition of glucose followed by testing in the ECL instrument (conventional analysis for NADH), would give a light signal depending on the activity of the enzyme, which in turn depends on the glucose
35 concentration.

The improvements of the invention over the prior art are set forth above. They include sensitivity, cost, and

ease of immobilization. Higher sensitivity (over comparable assays in which ruthenium and the nicotinamide cofactor are not attached to the dehydrogenase) results from advantages relating to the intramolecular nature of the electron transfer (Pam Liang and Mark Martin, unpublished ECL results). Cost savings will result from the reusable nature of the doubly-modified enzyme (easier recovery as opposed to recovery and reuse of the free enzyme, ruthenium complex, and nicotinamide cofactor). Finally, it would be impractical to separately immobilize all three components on a solid surface in a functional way. Coupling all three into one functional molecule allows solid phase immobilization (and hence convenience and reduce cost, compared to having enzyme, ruthenium, and cofactor free in solution).

Procedures for making NAD-labelled glucose dehydrogenase are known. Since dehydrogenases are a fairly conserved group of enzymes, similar methods could be used with other dehydrogenases. Procedures for labelling proteins (usually antibodies) with $\text{Ru}(\text{bpy})_3^{2+}$ -NHS ester (through lysins) are also well known (IGEN, Inc. technical notes).

The enzyme biosensor of the invention requires for use an ECL instrument and a solution containing analyte, such as glucose. A solution containing analyte (such as glucose) would be appropriately diluted, if necessary, and mixed in solution with enzyme biosensor. There are at least two ways the analyte could be measured; after fractional enzyme turnover and by rate measurements in the ECL instrument. For the fractional enzyme turnover method the ECL would be measured after a defined time period, less than the time required for all enzyme molecules to complete one turnover. If analyte concentration and time are appropriately adjusted, less than 100% of the enzyme molecules would have reacted with glucose, and less than maximal ECL would be generated. Based on the established kinetic parameters for the

reaction, glucose concentration could be determined. Alternatively, analyte concentration could be determined by rate measurements in the instrument. The enzyme reaction could be carried out at the same time the ECL reaction is in progress (such as by pulsing of voltage), so that NADH would be actively recycled and a rate measurement could be made.

The same system could be used without covalently attaching the reagents. Alternatively, a non-ECL system could be used without ruthenium (free enzyme and free NAD(P)⁺), where the UV absorbance of generated NAD(P)H could be monitored spectrophotometrically.

Novel NAD(P)H-like compounds could be used that are enzymatically active and also ECL active. Also, non-ruthenium ECL-active lumiphores could be used in place of Ru(bpy)₃²⁺.

DETAILED DESCRIPTION OF THE INVENTION

Mechanism of ECL excitation is as follows. Analyte is oxidized in the presence of the biosensor molecule of the invention which causes the NAD⁺ containing appendage to be converted to NADH. Ru(bpy)₃²⁺ (TAG) and NADH are oxidized at the surface of a gold electrode, forming Ru(bpy)₃³⁺ and NADH[•], respectively. (In this description, NAD⁺ and TAG are covalently attached to the dehydrogenase.) The NADH[•] spontaneously loses a hydrogen, forming NAD[•]. The NAD[•], a strong reductant, reacts with Ru(bpy)₃³⁺, a strong oxidant, forming the excited state of the detectant, Ru(bpy)₃^{2+*}. The excited state decays to the ground state through a normal fluorescence mechanism, emitting a photon having a wavelength of 620 nm.

Organic compounds which are suitable electrochemical detectants include, for example, rubene and 9,10-diphenyl anthracene. Many organometallic compounds are suitable electrochemical detectants, but of preferable use are Ru-containing compounds, such as ruthenium II tris-bipyridine chelate, and Os-containing

compounds. Detectants useful in the presently disclosed invention can be found in U.S. Patent 5,310,687, the contents of which are incorporated herein by reference.

These detectants are stable for long periods.

5 In addition, the detectants are safe and relatively inexpensive. They give a highly characteristic signal and do not occur in nature. Measurements based on luminescence of such detectants are sensitive, fast, reproducible and utilize simple instrumentation. The
10 signal is generated repeatedly by each molecule of the detectant, thereby enhancing the sensitivity with which these detectants may be detected. The preferred electrochemiluminescent detectants of the present invention are conveniently referred to herein as
15 $\text{Ru}(\text{bpy})_3^{2+}$. Various amounts of this detectant, or its equivalent, may be employed.

It is also to be noted that these detectants can be used directly in biological or food samples without pretreatment of sample.

20 The energy necessary for formation of the excited state arises from the large difference in electrochemical potentials of the $\text{Ru}(\text{bpy})_3^{3+}$ and NAD^{\cdot} . The excited-state $\text{Ru}(\text{bpy})_3^{2+}$ decays through a normal fluorescence mechanism, emitting a photon at 620 nm.
25 This process regenerates the original form of the $\text{Ru}(\text{bpy})_3^{2+}$, which is free to cycle multiple times through the reaction sequence. Each ECL-active detectant, therefore, can emit many photons during each measurement cycle, thereby enhancing detection.

30 Quantification of the $\text{Ru}(\text{bpy})_3^{2+}$ detectant can be readily automated with relatively uncomplicated instrumentation. The heart of an instrument is the electrochemical flow-cell, containing the working electrodes and counter electrodes for initiation of the
35 ECL reaction. Both of the electrodes are fabricated from gold, but other materials have been used with various degrees of success. A potentiostat applies various

voltage waveforms to the electrodes, and a single photomultiplier tube (PMT) detects the light emitted during the ECL reaction. An Ag/AgCl reference electrode is placed in the fluid path downstream from the flow cell, and a peristaltic pump is used to draw various fluids through the flow cell. In a typical sequence, the assay fluid is drawn from a test tube into the flow cell and the detectant is quantified by applying a ramp voltage to the electrodes and measuring the emitted light. After the measurement, a high-pH cleaning solution is drawn into the cell for an electrochemical cleaning procedure. A conditioning solution is then drawn into the cell, and a voltage waveform is applied that leaves the surfaces of the electrodes in a highly reproducible state, ready for the next measurement cycle.

The ECL reaction can be efficiently initiated by many different voltage waveforms. Measurements of the working electrode current and the ECL intensity are induced by the application of a triangle wave to the electrodes. The applied voltage as shown is actually the voltage measured at the Ag/AgCl reference electrode and includes the effects of a significant uncompensated resistance; consequently, the actual voltage applied at the working electrode is substantially less than that depicted. The triangle waveform rises from 565 to 2800 mV at a rate of 750 mV/s and then decreases at the same rate to 1000 mV. The current that flows in the cell is primarily the result of the oxidation of the analyte and the hydrolysis of water. Oxidation of both the analyte and $\text{Ru}(\text{bpy})_3^{2+}$ becomes evident when the applied voltage reaches ~1100 mV and produces a luminescence. The intensity of the luminescence increases with the applied voltage until the analyte at the surface of the electrode is depleted, resulting in decreased intensity. The intensity of the observed luminescence is great enough that it can easily be measured with conventional PMTs operating either in photon-counting or current modes.

After the sample is contacted with the biosensor, the ECL measurement is performed by application of electrical potential to the working electrode. This gives a characteristic signal from the emitted light. Relatively little interference results from background presented by the other materials present in the sample or added buffer.

Accordingly, the apparatus and methodology suitable for the performance of the process of this invention include, as noted earlier, those shown in US. Patent Nos. 5,068,088, 5,061,455, 5,093,268, and 5,147,806 and 5,221,605, which patents are expressly incorporated herein by reference. In addition, electrochemiluminescence molecules for use in the measuring system as detectants include those bidentate aromatic heterocyclic nitrogen-containing ligands of ruthenium and osmium described in U.S. Patent Nos. 5,310,687 and 5,310,687, which patents are expressly incorporated herein by reference.

Reagent kits containing the materials necessary for the performance of the assays can be assembled to facilitate handling, and foster standardization. Materials to be included in the kit may vary depending on the ultimate purpose. Typically the kit would include the modified enzyme mutein conjugate labelled at or near the active site with cofactor and TAG, necessary buffers, and standards. The kit may also include a measuring or detecting enzyme system depending upon application. The standards can be chemical reagents or data (empirical) in printed or electronic form necessary for the calibration necessary for performance of the assay.

Example 1: Preparation of an NAD⁺-Alcohol Dehydrogenase-Ru(bpy)₃²⁺ Conjugate

Bioconjugates can be made in which dehydrogenases are covalently linked to both an NAD⁺ analog and a derivative of Ru(bpy)₃²⁺. In these cases, the enzyme is not a mutant protein but rather is the naturally-occurring enzyme molecule. Use of the naturally-occurring enzyme has the advantage that no mutagenesis is required in order to prepare the conjugate. On the other hand, in some cases, preparation of a mutant enzyme may be preferred or essential because of unsatisfactory positioning of the natural amino acid sidechains that react with the NAD⁺ analog or the Ru(bpy)₃²⁺ derivative. The natural amino acids that react with the NAD⁺ or Ru(bpy)₃²⁺ derivatives may be absent or not properly positioned for either the enzyme reaction (requiring appropriate positioning of the NAD⁺ analog relative to the enzyme active site) or the ECL reaction (requiring appropriate positioning of the Ru(bpy)₃²⁺ derivative relative to the NAD⁺ analog).

Part 1: Preparation of the NAD-ADH Conjugate (based on M.-O. Månsson, et al., Eur. J. Biochem. 86, 455-463 (1978)).

ADH (equine liver alcohol dehydrogenase, Sigma Chemical Co., St. Louis, MO) will be dialyzed into 50 mM triethylamine, pH 7.5. To 5 mg of the dialyzed enzyme in 1.3 mL triethylamine buffer (4°C) (enzyme concentration about 0.1 mM) will be added that NAD⁺ analog (N⁶-([6-

aminohexyl]-carbamoylemethyl)- nicotinamide adenine dinucleotide, lithium salt, Sigma Chem. Co.) to a final concentration of 5 mM. Pyrazole (Sigma Chem. Co.) will be added to the solution to a concentration of 10 mM.

5 (Pyrazole stabilizes the enzyme-NAD⁺ complex so it can react (C. Woenckhaus et al., Bioorg. Chem. 12, 45-57 (1983).) The coupling agents, 1-ethyl-3(3-dimethyl-aminopropyl)-carbodiimide (EDC) and N-hydroxysuccinimide (NHS) will then be added in 500-fold and 250-fold molar

10 excesses (compared to enzyme subunit concentration, the enzyme is a dimer). EDC will be added in four equal portions at 12 hour intervals and NHS in two equal portions at 0 and 12 hours. The mixture is reacted for 48 hours, during which time the pH is kept at 7.5 using

15 additions of NaOH. After reaction for 48 hours, the solution will be dialyzed overnight against 3.0 L of 50 mM glycine, 50 mM sodium bicarbonate, pH 7.5. The solution will then be dialyzed three times (at least 6 hours each time) against 3 L of 50 mM bicarbonate, pH

20 8.0.

Part 2: Preparation of an NAD-ADH-Ru(bpy)₃²⁺ Conjugate (based on B.L. Plapp et al., J. Biol. Chem. 248, 3470-3475 (1973))

To the solution of the NAD-ADH conjugate prepared

25 above (in 50 mM NaHCO₃, pH 8.0) pyrazole will be added to a final concentration of 10 mM and (normal) NAD⁺ will be added to a final concentration of 2 mM. Amino groups

outside of the active site will be acetimidylated by adding 2.1 M ethyl acetimidate-HCl (Sigma Chem. Co.) (volume will be added to increase enzyme solution by 5%). (Stock solution of 2.1 M ethyl acetimidate will be made up fresh and pH adjusted to 8.0). The reaction will be allowed to go for one hour at 25° C, then three more additions of ethyl acetimidate will be made hourly (total reaction time = 4 hours). The protein will then be dialyzed extensively, against 33 mM sodium phosphate, 0.5 mM EDTA, 2.0 mM adenosine monophosphate, pH 8.0, then against 0.2 M sodium bicarbonate, pH 8.0. The external lysine-protected NAD-ADH will be reacted with an NHS ester derivative of $\text{Ru}(\text{bpy})_3^{2+}$ (IGEN, Inc., Gaithersburg, MD) by established means. Unreacted (free) $\text{Ru}(\text{bpy})_3^{2+}$ will be removed by dialysis against a neutral buffer. By comparison with literature reports only one $\text{Ru}(\text{bpy})_3^{2+}$ per enzyme subunit will be incorporated, on Lys 228 (See Brändén et al., Experientia Supplemental 36, J. Jeffrey, ed., Dehydrogenases, pp. 62-3.).

20 Example 2: Assays of NAD^+ -ADH- $\text{Ru}(\text{bpy})_3^{2+}$ Catalytic Activity

Assays 1 and 2 are based on M.-O. Månsson, et al., Eur. J. Biochem. 86, 455-463 (1978). Assay 3 is the electrochemiluminescent assay in which enzymatic conversion of ethanol by the NAD^+ -ADH- $\text{Ru}(\text{bpy})_3^{2+}$ conjugate is accompanied by light emission.

Assay 1: Spectrophotometric, Non-Regenerating Assay

This assay will reduce immobilized NAD^+ analog to the NADH analog. The reverse reaction will not occur (the assay is non-regenerating). The absorbance increase at 340 nm will indicate the concentration of immobilized NAD^+ analog ($\Delta\epsilon_{340}=6220 \text{ M}^{-1}\text{cm}^{-1}$).

In a cuvette, enzyme will be added ($\leq 1 \text{ mM}$) to 0.1 M sodium phosphate buffer (pH 7.2) containing 12 mM semicarbazide (Sigma Chem. Co.). The solution will be equilibrated at $25.0 \pm 0.1^\circ\text{C}$. Concentrated ethanol (final concentration = $500 \mu\text{M}$) is added in a small volume. The total absorbance change at 340 nm will be measured.

Assay 2: Spectrophotometric, Regenerating Assay

This assay will continually recycle immobilized NAD^+/NADH on the surface of the enzyme conjugate ($\text{NAD}^+-\text{ADH-Ru}(\text{bpy})_3^{2+}$). ADH itself will reduce NAD^+ to NADH upon oxidation of ethanol to acetaldehyde. A second enzyme, diaphorase (Sigma Chem. Co.), will be added which will convert $\text{NADH-ADH-Ru}(\text{bpy})_3^{2+}$ back to $\text{NAD}^+-\text{ADH-Ru}(\text{bpy})_3^{2+}$.

To assay for functional $\text{NAD}^+-\text{ADH-Ru}(\text{bpy})_3^{2+}$, the following solutions will be mixed in a cuvette, 200 μL 0.5 M Tris (pH 8.5), 100 μL 0.1% gelatin (in water, filtered), 10 μL 30 mM INT-Violet (in 10 mM phosphate buffer, pH 7.5, 10% DMSO, and 0.01% filtered gelatin), 10 μL diaphorase (10 mg/mL in 10 mM phosphate, pH 7.5), 30 μL ADH (or NAD-ADH or NAD-ADH-Tag), 650 μL 100 μM

ethanol. The absorbance of the mixture is continuously read in a spectrophotometer at 490 nm.

Assay 3: Electrochemiluminescent Assay

The assay is performed similarly to Assay 1 (above).

5 However, instead of measuring the absorbance increase when ethanol is added, similar enzyme conjugate solutions (with and without added ethanol) will be measured in an IGEN ECL Analyzer (IGEN, Inc., Gaithersburg, MD). In the absence of ethanol the enzyme conjugate will be in the form $\text{NAD}^+\text{-ADH-Ru(bpy)}_3^{2+}$ (non-electrochemiluminescent).
10 Following enzymatic conversion of ethanol to acetaldehyde, the enzyme conjugate will be in the form $\text{NADH-ADH-Ru(bpy)}_3^{2+}$ (electrochemiluminescent). Moreover, voltage is applied to the enzyme conjugate in the ECL
15 instrument, light is emitted, and the conjugate returns to the original form ($\text{NAD}^+\text{-ADH-Ru(bpy)}_3^{2+}$). This original form can then catalyze oxidation of another molecule of ethanol, which would convert the enzyme conjugate once against to the electrochemiluminescent NADH form. Thus,
20 multiple photons can be generated by the enzyme conjugate in the presence of ethanol.

Example 3: Preparation of a NAD^+ -Mutant Glucose Dehydrogenase- Ru(bpy)_3^{2+}

In this example, a glucose dehydrogenase mutant will
25 be prepared to contain a strategically-located surface sulfhydryl group which can react with an NAD^+ analog to produce an NAD^+ -enzyme conjugate. The mutation is

positioned so that the tethered NAD^+ molecule can bind to the NAD^+ binding site in the enzyme and be enzymatically efficiently reduced to NADH. The mutant glucose dehydrogenase- NAD^+ conjugate will then be reacted with an

5 N-hydroxysuccinimide (NSH) derivative of $\text{Ru}(\text{bpy})_3^{2+}$ to yield a doubly-modified enzyme; $\text{NAD}^+\text{-GlcDH-Ru}(\text{bpy})_3^{2+}$. This enzyme conjugate will be luminescent in an ECL instrument. For every glucose molecule that the enzyme catalyzes, the surface NAD^+ will be converted to NADH. In

10 an ECL instrument (IGEN, Inc., Gaithersburg, MD), NADH but not NAD^+ will cause enzyme surface-immobilized $\text{Ru}(\text{bpy})_3^{2+}$ to emit a photon of light. Thus, a molecule of glucose will result in a photon of light to be emitted by the doubly-modified enzyme. Moreover, in the ECL

15 process, NADH is reconverted to NAD^+ . Thus, the doubly-modified enzyme is regenerated by emitting light and can be used repeatedly.

Part 1: Preparation of the Mutant GlcDH.

Mutant GlcDH has been previously prepared by site-

20 directed mutagenesis (M. Persson, et al., Bio/Technology (1991) 9,280-284). The residue asp⁴⁴ in glucose dehydrogenase was mutated to a cys⁴⁴ by standard mutagenesis protocol. The mutant protein (GlcDHcys⁴⁴) was expressed in E. coli and purified by conventional means.

Part 2: Preparation of a Cysteine-Reactive NAD⁺ Derivative.

A thiol reactive NAD⁺ analog has been prepared (M. Persson, et al., Bio/Technology (1991) 9, 280-284).

5 Essentially, the method involves reaction of two commercially-available reagents; N-succinimidyl-3-[2-pyridyldithio]propionate (SpDP; Pierce Chem. Co.) and N⁶[6-aminohexyl-(carbamoylmethyl)-NAD (Sigma Chem. Co.). The resulting product will react with the GlcDHcys⁴⁴ to
10 yield the desired NAD⁺-modified enzyme. Such an NAD⁺-labelled GlcDH has been prepared (M. Persson, et al., Bio/Technology (1991) 9, 280-284).

Part 3: Preparation of NAD⁺-GlcDHcys⁴⁴-Ru(bpy)₃²⁺

The NAD⁺-GlcDHcys⁴⁴ molecule prepared in Part 2 will
15 be reacted with an NHS ester derivative of Ru(bpy)₃²⁺ (IGEN, Inc.) using established protocols (0.2 M NaHCO₃, pH 8.0, room temperature) for reactions of this reagent with proteins (IGEN technical notes). One or more lysine residues on the surface of NAD⁺-GlcDHcys⁴⁴ will be
20 covalently linked to Ru(bpy)₃²⁺ as a result of the reaction. Following the reaction, free unreacted Ru(bpy)₃²⁺ will be removed by dialysis to yield NAD⁺-GlcDHcys⁴⁴-Ru(bpy)₃²⁺.

25 Example 4: ECL Detection of Glucose Using NAD⁺-GlcDHcys⁴⁴-Ru(bpy)₃²⁺

NAD⁺-GlcDHcys⁴⁴-Ru(bpy)₃²⁺ will concurrently oxidize glucose to gluconolactone and reduce immobilized NAD⁺ to

NADH. Next, in an ECL instrument (IGEN, Inc., Gaithersburg, MD), enzyme-immobilized NADH will efficiently cause neighboring immobilized $\text{Ru}(\text{bpy})_3^{2+}$ to emit light. Thus, the doubly-modified enzyme will report the presence of glucose by emitting light.

In the test tube, enzyme ($\text{NAD}^+\text{-GlcDHcys}^{44}\text{-Ru}(\text{bpy})_3^{2+}$) will be added ($\leq 1 \mu\text{M}$) to 0.1 M sodium phosphate buffer (pH 7.2). The solution will be equilibrated at $25.0 \pm 0.1^\circ\text{C}$. A glucose-containing solution is added in a small volume. In the absence of glucose the enzyme conjugate will be in the form $\text{NAD}^+\text{-GlcDHcys}^{44}\text{-Ru}(\text{bpy})_3^{2+}$ (non-electrochemiluminescent). Following enzymatic conversion of glucose to gluconolactone, the enzyme conjugate will be in the form $\text{NADH-GlcDHcys}^{44}\text{-Ru}(\text{bpy})_3^{2+}$ (electrochemiluminescent). Moreover, when voltage will be applied to the enzyme conjugate in the ECL instrument, light is emitted, and the conjugate returns to the original form ($\text{NAD}^+\text{-GlcDHcys}^{44}\text{-Ru}(\text{bpy})_3^{2+}$). This original form can then catalyze oxidation of another molecule of glucose, which would convert the enzyme conjugate once again to the electrochemiluminescent NADH form. Thus, multiple photons can be generated by the enzyme conjugate in the presence of glucose.

Although the examples illustrate various modifications of the present invention, other variations will suggest themselves to those skilled in the art in light of the above disclosure. It is to be understood,

therefore, that changes may be made in the particular embodiments described above which are within the full intended scope of the inventions as defined in the appended claims.

WHAT IS CLAIMED IS:

1. An oxidoreductase conjugate capable of generating a chemiluminescent signal comprising a co-factor and a TAG moiety separately linked in close proximity to an active site of the dehydrogenase in a manner which permits their electrochemical interaction with each other and a substrate contained within the active site.
2. The oxidoreductase conjugate of claim 1 wherein oxidoreductase is a dehydrogenase is selected from the group consisting of glucose dehydrogenase, alcohol dehydrogenase and lactate dehydrogenase.
3. The dehydrogenase conjugate of claim 2 wherein the dehydrogenase is glucose dehydrogenase.
4. The dehydrogenase conjugate of claim 3 wherein the co-factor is NADH and the TAG is $\text{Ru}(\text{bpy})_3^{2+}$.
5. The dehydrogenase conjugate of claim 3 wherein the TAG is covalently attached to a lysine located near the active site.
6. The dehydrogenase conjugate of claim 3 wherein the co-factor is covalently linked to a cysteine located near the active site.

7. A biosensor comprising an oxidoreductase conjugate of claim 1.

8. The biosensor of claim 7 wherein the oxidoreductase is functionally affixed to an electrode.

9. The biosensor of claim 7 wherein the oxidoreductase is immobilized.

10. The biosensor of claim 7 further comprises an electrode which is located in close proximity to the oxidoreductase conjugate to permit the optimal inducement of TAG to generate a luminescent signal.

11. The biosensor of claim 10 wherein the oxidoreductase conjugate is immobilized to the electrode.

12. A method for the determination of the concentration of an enzyme substrate in a specimen comprising the steps of:

(a) contacting said specimen containing said enzyme substrate with the oxidoreductase conjugate of claim 1 under conditions which permit the oxidation of the enzyme substrate;

(b) measuring the change in chemiluminescent from a base reading; and

(c) determining the concentration of enzymatic substrate based on the measured change in chemiluminescent signal.

13. The method according to claim 12 wherein the measurement and determination is done on a real time basis.

14. The method according to claim 12 wherein the determination of enzymatic substrate is deduced from a comparison with established kinetic parameters for the reaction.

15. The method according to claim 12 wherein the determination of enzymatic substrate concentration is determined based on rate measurements in the instrument.

16. The process of claim 12 wherein the steps are carried out simultaneously.

17. The process of claim 16 wherein the voltage necessary for chemiluminescence is pulsed so as to actively recycle co-factor and TAG.

18. A method for measuring the presence of analyte comprising,

- (a) contacting a sample suspected of containing an analyte with a biosensor of claim 7,
- (b) subjecting the contacted sample of step (a) to conditions which result in electrochemiluminescence;
- (c) measuring the resulting electrochemiluminescence to obtain a reading; and
- (d) determining the concentration of enzymatic substrate based on the measured change in chemiluminescent signal reading.

19. A kit suitable for the performance of an electrochemiluminescent assay comprising, the oxidoreductase conjugate of claim 1 and suitable buffer systems.

20. The kit of claim 19 wherein the dehydrogenase conjugate is immobilized to a solid surface.

21. The oxidoreductase conjugate of claims 1 wherein the conjugate is immobilized to a solid surface.

22. A method for converting an oxidoreductase substrate to its oxidized form comprising,

- (a) contacting the substrate with the oxidoreductase of claim 1 under conditions

which promote enzymatic oxidation of the
substrate, and
(b) recovering the oxidized substrate.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/09869

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : C12Q 1/32; C12N 9/04; G01N 21/64, 21/76

US CL : 435/26, 190; 422/52, 61, 82.07

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/26, 190; 422/52, 61, 82.07

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS

Search Terms: NAD or NADH, conjugat? or crosslink or linked, dehydrogenase, electrochemilumin?

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,310,687 A (BARD et al.) 10 May 1994, see entire document especially column 9, lines 3-60.	1-22
Y	US 5,264,092 A (SKOTHEIM et al.) 23 November 1993, see entire document.	1-22
Y	MÅNSSON et al. Covalent Binding of an NAD Analogue to Liver Alcohol Dehydrogenase Resulting in an Enzyme-Coenzyme Complex not Requiring Exogenous Coenzyme for Activity. Eur. J. Biochem. 1978, Volume 86, pages 455-463, see entire document.	1-22

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* T	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A document defining the general state of the art which is not considered to be of particular relevance	* X	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* E earlier document published on or after the international filing date	* Y	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	* A	document member of the same patent family
* O document referring to an oral disclosure, use, exhibition or other means		
* P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

25 SEPTEMBER 1996

Date of mailing of the international search report

09 OCT 1996

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JON B. WEBER, Ph.D.

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US96/09869

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	PERSSON et al. Continuous Regeneration of NAD(H) Covalently Bound to a Cysteine Genetically Engineered into Glucose Dehydrogenase. Bio/Technology, March 1991, Volume 9, pages 280-284, see entire document, especially page 280 column 1.	1-22
Y	BLACKBURN et al. Electrochemiluminescence Detection for Development of Immunoassays and DNA Probe Assays for Clinical Diagnostics. Clin. Chem. September 1991, Volume 37, Number 9, pages 1534-1539, see entire document.	1-22